An announcement from ANGLE plc ( (GB:AGL) ) is now available.
ANGLE plc announced the presentation of independent findings by Weill Cornell Medicine at the San Antonio Breast Cancer Symposium, supporting ANGLE’s HER2 assay development program. The Parsortix-based HER2 workflow could revolutionize patient stratification for treatment with HER2 antibody drug conjugates (ADCs) by providing a semi-automated, quantitative assessment of HER2 status in circulating tumor cells (CTCs). This is particularly impactful as HER2 status often changes over time, and the new method could allow for real-time assessment, enabling better-targeted treatments and potentially expanding the eligibility for ADC therapies to patients previously classified as HER2-negative.
More about ANGLE plc
ANGLE plc is a leading company in the liquid biopsy industry, specializing in innovative circulating tumor cell (CTC) solutions applicable in research, drug development, and clinical oncology. Their flagship technology, the Parsortix® PC1 System, is FDA cleared and used for comprehensive analysis of blood samples to aid in diagnostics and personalized medicine.
YTD Price Performance: -4.09%
Average Trading Volume: 1,295,286
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £36.28M
For an in-depth examination of AGL stock, go to TipRanks’ Stock Analysis page.